In therapeutic AAV manufacturing, the ability to detect and quantify a specific recombinant AAV (rAAV) without cross-reacting to other serotypes is a genuine technical challenge. During production, ensuring no contamination with other viruses is critical, and any off-target reactivity can compromise quality control. AAV capsid proteins are structurally conserved across serotypes, which means conventional antibody development approaches often yield reagents that are not specific, cross-reacting with native AAV or recombinant AAV.
Here we walk through how Exonbio approached a recent client project: developing rabbit recombinant monoclonal antibodies with strict specificity for a proprietary rAAV capsid variant (rAAV-DAD), with confirmed zero cross-reactivity to a panel of related AAV serotypes.
Why Standard Approaches Fall Short
When a client comes to us needing antibodies against a novel rAAV target, one of the first questions we ask is: what does “specific” really mean for this application? In the case of rAAV-DAD, the requirement was clear: the antibodies needed to recognize DAD and nothing else in the AAV family, as any cross-reactivity would pose a contamination risk during therapeutic manufacturing. That is a high bar given how similar capsid architectures can be across serotypes – especially since DAD differs from AAV9 by only a couple of amino acids.
Simply immunizing an animal and screening outputs by ELISA can yield reactive clones, but not necessarily specific ones. A polyclonal immune response will mount antibodies against epitopes shared across serotypes, and without deliberate counter-selection, many of those clones will make it through standard screening undetected until they cause problems downstream. Polyclonal titer assays confirmed the challenge: bleeds showed the same titer against DAD, AAV9, and KT143, showing standard immunization alone could not generate the required specificity.
Our approach addresses this at the earliest possible step: the cell sort itself.
Counter-Selection Built Into the Sort
The key to this project’s success was embedding specificity decisions directly into the plasma cell isolation stage, before any cloning or screening takes place.
After immunization and serum titer confirmation, we harvested splenocytes and used a dual-selection FACS sorting strategy. Cells were exposed simultaneously to a positive selection probe (the rAAV-DAD antigen, fluorescently labeled) and a counter-selection cocktail of related rAAV serotypes – including AAV9 and KT143 – labeled with a separate fluorescent channel. Only plasma cells that bound the DAD probe and showed no signal on the counter-selection channel were sorted and advanced.
Multicolor FACS sorting with simultaneous positive and counter-selection is a well-established approach in antibody discovery. What made this application distinctive was how it was implemented: rather than filtering for cross-reactivity at the ELISA screening stage – which is where most workflows catch the problem – the counter-selection was built directly into the plasma cell sort itself. Cross-reactive B cells were physically excluded from the pipeline before any cloning or screening took place, ensuring that every clone advanced matched the required specificity profile.
Specificity Confirmed Across the Board
Following sorting, antibody heavy and light chain sequences were amplified, expressed, and supernatants were screened by ELISA against the target and each AAV in the counter-selection panel individually. Every confirmed DAD-positive clone showed zero cross-reactivity to AAV9, KT143, and other related serotypes tested – a direct result of the upfront sorting strategy. This level of specificity is essential for manufacturing applications where viral contamination must be strictly avoided.
From Clone to Delivered Antibody
Selected clones were carried through sequence deconvolution, a proofreading step that eliminates PCR-introduced errors and ensures the expressed sequence faithfully represents the authentic B cell-derived antibody, and then produced in HEK293 suspension culture. Purified antibodies were delivered alongside full heavy and light chain sequences and plasmid DNA, giving the client everything needed for in-house re-expression or further development.
What This Means for rAAV Antibody Development
If your process only filters for cross-reactivity at the ELISA stage, you may miss the opportunity to eliminate cross-reactive clones earlier. Integrating counter-selection at the FACS sort step means the clones you amplify, sequence, and produce are already pre-enriched for antibody clones specific to the target – even when the target differs from related serotypes by only a few amino acids.
For gene therapy teams working with proprietary or novel rAAV capsid variants – where commercial antibodies do not exist and off-target reactivity would compromise manufacturing quality control – this kind of purpose-built approach makes a material difference.
If you are developing detection tools for a novel rAAV target, we would be glad to discuss how Exonbio’s SPIN® platform can be tailored to your specificity requirements.